ANI Pharma (ANIP) Misses Q2 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/5/2026
- Nasdaq notches record high close as investors focus on earnings
- Oil slips on rising Mideast crude exports, G7 stocks release
- Intel stock slides as TSMC explores Terafab tie-up, analyst flags share losses
- Schneider Electric to acquire PTC for $22.6 billion in all-cash deal
- Five things to watch in markets in the week ahead
Tweet
Share
E-mailGet Alerts ANIP Hot Sheet
Join SI Premium – FREE
ANI Pharma (NASDAQ: ANIP) reported Q2 EPS of $0.67, $0.01 worse than the analyst estimate of $0.68. Revenue for the quarter came in at $48.6 million versus the consensus estimate of $48.05 million.
For earnings history and earnings-related data on ANI Pharma (ANIP) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SpaceX (SPCX) PT Raised to $230 at Goldman Sachs ahead of earnings release
- Raymond James Reiterates Outperform Rating on Camping World Holdings (CWH)
- ANI Pharmaceuticals to present eye implant data at AAO 2026 meeting
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
